FY2026 medical budget lines and team-level resource capacity. All figures USD; FY2026 exchange-rate snapshot of 2 Jan 2026.
Planned
Committed
Actual
Forecast at year end
Overrun-risk rule (MET-071): committed > planned, or actual ÷ planned > 0.75 × 1.05 = 78.75% with 71% of the fiscal year elapsed. Forecast is a straight-line assumption: actual ÷ 0.71. It ignores seasonality and known one-off commitments.
USD millions
| Product | Planned | Committed | Actual |
|---|---|---|---|
| Vantrexa | $8.4M | $7.34M | $5.13M |
USD millions, sorted by planned
Largest category: Personnel ($3.02M planned). 11 categories in the current filter.
MET-070 monthly history (Global, % of planned) against an even 1/12-per-month plan line. Filters do not apply to this series.
Latest: 71% consumed by Sep versus 75% on the straight line. Consumption above the line means spend is running ahead of an even phasing.
| Line | Product | Region | Function | Category | Initiative | Vendor | Planned | Committed | Actual | Variance | Consumed | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BL-001 | Vantrexa | Global | Field Medical | Personnel | INI-0101 | — | $2.4M | $2.4M | $1.8M | $620k | 74% | On plan |
| BL-002 | Vantrexa | Global | Medical Communications | Publication | INI-0103 | Kessler Medical Writing | $420k | $380k | $262k | $158k | 62% | On plan |
| BL-003 | Vantrexa | Global | Medical Communications | Congress | INI-0106 | — | $1.1M | $1.1M | $698k | $432k | 62% | On plan |
| BL-004 | Vantrexa | Europe | Field Medical | Medical education | INI-0104 | — | $380k | $366k | $296k | $84k | 78% | On plan |
| BL-005 | Vantrexa | Global | Evidence Generation | Research | INI-0102 | Meridian Health Analytics | $1.4M | $620k | $310k | $1.1M | 21% | On plan |
| BL-006 | Vantrexa | Global | Medical Communications | Agency | INI-0105 | Clearview Health Communications | $640k | $610k | $512k | $128k | 80% | Overrun risk |
| BL-007 | Vantrexa | Global | Leadership | Advisory boards | — | — | $310k | $290k | $244k | $66k | 79% | On plan |
| BL-008 | Vantrexa | Global | Field Medical | Travel | — | — | $480k | $480k | $388k | $92k | 81% | Overrun risk |
| BL-009 | Vantrexa | Asia-Pacific · JP | Field Medical | Personnel | INI-0107 | — | $620k | $620k | $372k | $248k | 60% | On plan |
| BL-010 | Vantrexa | Asia-Pacific · JP | Medical Communications | Translation | — | — | $140k | $120k | $68k | $72k | 49% | On plan |
| BL-011 | Vantrexa | Global | Medical Operations | Technology | — | — | $220k | $220k | $165k | $55k | 75% | On plan |
| BL-012 | Vantrexa | Global | Evidence Generation | Data | — | — | $210k | $180k | $35k | $175k | 17% | On plan |
Team-level analytics only
8 of 10 teams have demand above capacity.
| Team | Region | Function | Capacity FTE | Demand FTE | Utilisation | Contractor FTE | Critical roles | Allocations by initiative |
|---|---|---|---|---|---|---|---|---|
| Field Medical — US Oncology | North America | Field Medical | 8 | 8.6 | 108% | 0 |
| |
| Field Medical — EU Oncology | Europe | Field Medical | 10 | 10.2 | 102% | 1 | — | |
| Field Medical — Japan | Asia-Pacific | Field Medical | 1 | 2 | 200% | 0 |
|
|
| Field Medical — Nephrology | Europe | Field Medical | 3 | 3.4 | 113% | 0 |
| |
| Field Medical — Neurology | Global | Field Medical | 6 | 5.1 | 85% | 0 | — | |
| Medical Communications | Global | Medical Communications | 5 | 6.1 | 122% | 2 |
| |
| Medical Information | Global | Medical Information | 9 | 9.8 | 109% | 1 | — | |
| Evidence Generation & HEOR | Global | Evidence Generation | 4 | 4.9 | 123% | 1 |
| |
| Medical Operations | Global | Medical Operations | 3 | 2.8 | 93% | 0 | — | Not allocated to initiatives |
| Compliance & Quality (MA-aligned) | Global | Compliance | 1 | 1.7 | 170% | 0 |
| Not allocated to initiatives |